Combining professional development with real world application.

A dedicated service team with deep experience and expertise .

Advisory Board


Prof. Dr. Bernhard Lieb 

Johannes Gutenberg-Universität Mainz

Institut für molekulare Physiologie

Dr. Tom Robinson is an independent research group leader at the Max Planck Institute of Colloids and Interfaces in Potsdam. His research is primarily funded by the MaxSynBio network - a consortium with the common goal of creating artificial cells from the bottom-up. His group develops novel microfluidic platforms for the de novo creation and analysis of synthetic cells for synthetic biology applications. Complimentary to the traditional “top-down” synthetic biology, the “bottom-up” approach takes non-living components such as lipids or proteins and assembles them in such a way as to mimic the structure and function of natural cells. Tom Robinson’s lab uses synthetically produced lipids and microfluidic droplet technology to create enclosed vesicle compartments which serve as artificial cells. These containers act much in the same way as real cells where the essential machinery for life is enclosed against the outside environment and membrane channels can be reconstituted to allow substrate and product transport. One of their current objectives is to mimic the hierarchical structure of the Eukaryotic cell where the membrane bound sub-cellular organelles are represented by multi-compartment lipid vesicles. These bio-inspired systems are used as platforms to study cellular function and to support the biosynthesis of compounds.

Dr. Tom Robinson 

Max Planck Institute of Colloids and Interfaces

Biomicrofluidic Systems

Prof. Dr. Bernhard Lieb habilitated in Mainz in 2002 on the "Molecular structure and evolution of mollusc hemocyanins" and has been a full professor at the Johannes Gutenberg University Mainz at the Institute of Molecular Physiology (imP) since 2011.
His research includes molecular biological analysis of the structure, evolution, and function of mollusc hemocyanins with emphasis on the evolution of paralogous and orthologous hemocyanin genes as well as a transcriptional and developmental expression control.
In addition to the above-mentioned research field of malacology, more in-depth research has also been taking place in the field of nutracognosy for several years.
Further areas of responsibility of Prof. Dr. Bernhard Lieb:
He is an expert for the NEM, genetic engineering, pharmaceuticals, including pharmaceutical cannabis; state-approved pharmaceutical consultant; BTM representative; SAB member at Synbionik as well as a member of the editorial board of various journals.

Prof. Dr. Jesko Köhnke 

Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) 
Structural biology of biosynthetic enzymes


Dr. Jesko Köhnke obtained his PhD from Columbia University in 2010, where he focused on structural biology. After a PostDoc at the University of St Andrews he became an Emmy Noether junior group leader at the Helmholtz Institute for Pharmaceutical Research Saarland in 2015. Since 2020 he is a Reader in the School of Chemistry at the University of Glasgow.

His research focuses on the biochemical and structural elucidation of novel enzymatic transformations, particularly those of peptides. The overall, long-term goal of his work is the tailoring and improvement of natural products with anti-bacterial or anti-cancer activity. This includes semisynthetic approaches to explore new chemical space covered for a given compound. As a result he holds shares of several patents for engineered enzymes that enable the production of modified peptides. In addition he collaborates with groups seeking structural data to understand biological phenomena as well as medicinal chemists to provide structural insights for rational compound development.

Advisory Board


Thomas Ebeling

Bernd Miehler

Dr. Kemal Malik

Thomas Ebeling has studied psychology at the University of Hamburg.


After graduating, Ebeling started his career at Reemtsma, where he was responsible for the "West" brand as a product manager. In 1991 Ebeling joined Pepsi-Cola, Germany, where held various director positions in marketing and sales. In 1996 he was assigned to be the General Manager of Pepsi-Cola Germany.


In 1997 Ebeling joined Novartis as the General Manager of Novartis' Nutrition for Germany and Austria. Following, he took over the Global Management of the Nutrition Division and became a member of Novartis' Executive Board. In 2000 he became Novartis' Global Pharmaceutical Business Chief Executive Officer ("CEO") and in 2007 the CEO of the Novartis Consumer Health Division.


Between 2009 and 2018, Ebeling was the CEO of ProSiebenSat.1 Media. Since 2017 Ebeling has been a professional Non-Exec Board Member and advises a wide range of companies and owners. Besides, he has been a member of the Board of Directors of Lonza Group since April 2013.

Bernd Miehler studied business administration and process engineering at the University of Stuttgart and at the University of Massachusetts in Dartmouth, USA.


Previously, Miehler was the senior vice president program office and member of the group management at Jet Aviation AG in Switzerland, the global leader in business aviation. There he was responsible for corporate transformation and acquisition.


Miehler also worked as a senior manager at the leading international management consultancy A.T. Kearney in the areas of operations and M&A. He also worked on international projects in leading positions in Brazil and Germany.

From 2014 to 2020, Miehler was Executive Vice President at TeamViewer, leading Corporate Development. He was responsible for managing all internal workstreams of TeamViewers IPO, which was amongst the largest German tech IPOs. 

Dr. Kemal Malik holds a medical and a surgery degree from the University of London and the Faculty of Medicine at Imperial College London.


Dr. Malik has had an outstanding career through a variety of senior and C-level positions in the pharmaceutical industry, making him an experienced industry leader.


He held various positions in medical affairs and clinical development at Bristol-Myers Squibb in the UK. In 1995 he joined Bayer AG's Pharmaceuticals Business Group and was then named Head of Global Medical Development before being appointed Head of Global Development and Head of LEAPS. His area of responsibilities also covered the strategic venturing of Bayer, achieving groundbreaking innovations.


Between 2014 and 2019, Dr. Malik was a member of Bayer AG's Board of Management and was responsible for the Innovation Business of Bayer Group.

Jan Beckers

Nikita Fahrenholz

Jan Beckers has a diploma degree in business administration from the University of Münster


Beckers is one of the leading German serial entrepreneurs and investors, who started investing at the age of 16 and started building companies as early as 20. Beckers is the founder of companies such as Absolventa, Fyber, finleap, Heartbeat Labs, and IONIQ Group, invested in Delivery Hero in the early stages and invested in Facebook as well as Linkedin before the IPO. 


As Executive Chairman of the IONIQ Group, his responsibilities include strategy, investments, and strategic partnerships. Doubtless, Beckers has the instinct and determination for bold moves into uncharted territory. His success proves him right. In 2014, Beckers was awarded as "Entrepreneur of the Year" by Ernst & Young, Germany.

Nikita Fahrenholz holds a degree in business administration from the ESB Reutlingen and the Lancaster University. 


He is one of the most successful start-up entrepreneurs in Germany. After his studies, Fahrenholz joined McKinsey & Company as a consultant. With and Book A Tiger, he has built up two very well-known companies. 


In 2011, after founding, he initiated the merger with Delivery Hero and was a member of the global management team with responsibility for strategy and operations until 2014.


With co-founder Claude Ritter, he subsequently founded Book A Tiger – a platform solution to connect businesses and private customers with cleaning and additional household services. Fahrenholz was CEO here until 2018 and since 2018 Chairman of the Board. In 2019, he started another project: Fahrengold, a start-up that offers the “garages of the future”. Fahrenholz has received several awards. Among others, the Financial Times voted him number 2 of European Tech Entrepreneurs. 

Synbionik was founded in early 2019. Its headquarter is in Frankfurt/Main, Germany.